The Latest Breaking News from FDA

Gainers Ontrak, Inc. (NASDAQ: OTRK) gained 102% to $1.3150. Ontrak is expected to report financial results for the second quarter on Tuesday, August 9, 2022.

The Food and Drug Administration placed a cancer study from Beam Therapeutics on hold Monday, leading Beam stock to topple.

The FDA has effectively thrown up its hands over its most important food-related role.

Though doctors and advocates have helped speed up access to the antiviral pills – of which the U.S. has enough to treat 1.7 million people – health providers are few and forms are still required.

The U.S. Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics’ (NASDAQ:ARQT) New Drug Application (NDA) for ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis in patients 12 years of age or older. The company expects commercial launch of the product in Mid-August. Arcutis shares traded in a range of…

Here's a roundup of top developments in the biotech space over the last 24 hours:

CHARLOTTE, N.C. — As COVID-19 cases soar around the country, fake treatments continue to linger on the open market, posing a safety risk to those seeking medical care.

The Court should assimilate the “major questions” doctrine of West Virginia v. EPA and its precedents—including Chevron and what came even before that—to an approach that asks whether Congress has made an actual delegation. Only this will serve the relevant separation-of-powers principle.

Mark Grenon, who runs a ‘non-religious church’, charged for selling toxic industrial bleach as Covid cure